🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05782270
Recruiting Phase 4

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

NCT05782270 · tracked via the Priya Life Science China tracker
Sponsor
China National Center for Cardiovascular Diseases
Phase
Phase 4
Started
2023-04-11
Last updated
2025-11-18

Condition(s) studied

AnticoagulationCoronary Endarterectomy

Investigational drug(s) / intervention(s)

Warfarin →DAPT →CE+CABG

Warfarin: dual antiplatelet therapy combined with warfarin

DAPT: Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)

CE+CABG: Coronary endarterectomy combined with coronary artery bypass grafting

Study summary

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period. * No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin. * Must be able to swallow tablets after the surgery. Exclusion Criteria: 1. Patients with high bleeding risk (HAS-BLED ≥ 3); 2. Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time; 3. Emergency surgery; 4. Serum creatinine \>130μmol/L, or significant liver dysfunction (elevated ALT and/or AST); 5. History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding; 6. History of hemorrhagic stroke, or platelet dysfunction; 7. Allergic or with contraindication to any of aspirin, clopidogrel or warfarin; 8. Participated in other clinical trial for drug or device within 30 days; 9. Pregnant or planning to be pregnant.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing Municipality Recruiting

On this site

📄 Coumadin (warfarin) drug profile →

More China National Center for Cardiovascular Diseases trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05782270 on ClinicalTrials.gov ↗ ← All trials in China